Price
No data yet.
Social Signal Score
Analyst Ratings
20 analystsRevenue
$56.50MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Alan H. Auerbach
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 179
- Beta
- 1.23
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- -1.57
Financials
Revenue
$56.50M+829.8%Net Income
$8.19MEBITDA
$13.53MFree Cash Flow
$1.62MEPS (diluted)
$0.16Shares Outstanding (diluted)
52.60M+61.8%Operating Expenses
$36.44MCash & Debt
$93.90MRevenue by Segment (annual)
$228.37MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $228.37M | $31.11M | $0.62 |
| 2024 | $230.47M | $30.28M | $0.62 |
| 2023 | $235.64M | $21.59M | $0.46 |
| 2022 | $228.03M | $2.0K | $0.02 |
| 2021 | $253.16M | $-29.13M | $-0.72 |
| 2020 | $225.11M | $-59.99M | $-1.52 |
| 2019 | $272.26M | $-75.59M | $-2.13 |
| 2018 | $251.00M | $-113.60M | $-2.99 |
| 2017 | $27.70M | $-292.00M | $-7.86 |
| 2016 | $0.00 | $-276.00M | $-8.29 |
| 2015 | $0.00 | $-239.30M | $-7.45 |
| 2014 | $0.00 | $-142.00M | $-4.73 |
| 2013 | $0.00 | $-54.66M | $-1.90 |
| 2012 | $0.00 | $-74.30M | $-3.42 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.91
- Implied price
- $9.14
- Return from $9.60
- -1.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $4.54 — -52.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 6 | 8 | 10 | 12 | 14 |
|---|---|---|---|---|---|
| -2.0% | -18.9% | -14.1% | -10.1% | -6.8% | -3.9% |
| 3.0% | -14.7% | -9.7% | -5.6% | -2.1% | 1.0% |
| 8.0% | -10.6% | -5.3% | -1.0% | 2.7% | 5.9% |
| 13.0% | -6.5% | -0.9% | 3.6% | 7.5% | 10.8% |
| 18.0% | -2.3% | 3.5% | 8.2% | 12.2% | 15.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newszacks.com·1d ago·Neutral
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
View source ↗ - Newsbusinesswire.com·2d ago·Neutral
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology has initiated ALISCA®-Lung2, a Phase II trial of alisertib in combination with paclitaxel to treat advanced small cell lung cancer.
View source ↗
Earnings
Thu, Nov 5(in 7 weeks)
Consensus estimate $0.11 per share
Typical surprise +133.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.19 vs $0.04beat
- Thu, May 7$-0.04 vs $-0.13beat
- Thu, Feb 26$0.29 vs $0.24beat
- Thu, Nov 6$0.21 vs $0.09beat
- Thu, Aug 7$0.15 vs $0.11beat
- Thu, May 8$0.10 vs $0.02beat
Estimates and results for PBYI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PBYI officers and directors.
- Bought
- —
- Sold
- $3.7m
0 trades
51 trades
- Wilson Troy Edwardsold
- Cesano Alessandrasold
- Auerbach Alan Hsold
- Hunt Douglas Msold
- Nougues Maximo Fsold
- Wilson Troy Edwardsold
- Stuglik Brian Msold
- Senderowicz Adriansold
49 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (348d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (460d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.